pANCA (anti-myeloperoxidase, anti-leukocyte elastase)

Introduction

Also see pANCA in serum

Etiology

• directed against myeloperoxidase
  • Churg-Strauss syndrome (60-70%)
  • microscopic polyangiitis (75-80%)
  • idiopathic crescentic glomerulonephritis (80%)
  • polyarteritis nodosa
  • Wegener's granulomatosis (20%)
• directed against leukocyte elastase, lactoferrin
  • vasculitis
  • primary sclerosing cholangitis (60-85%)
  • ulcerative colitis (60-75%)
  • primary biliary cirrhosis (30-40%)
  • rheumatoid arthritis
    • with Felty's syndrome (90-100%)
    • with vasculitis (50-75%)
    • uncomplicated (20-40%)
  • systemic lupus erythematosus (25%)
  • drug-induced lupus erythematosus
    • minocycline, hydralazine
  • 5% of normal subjects
• p-ANCA may also be positive in:
  • autoimmune chronic hepatitis
  • hepatitis C
  • sulfasalazine toxicity
  • Crohn's disease (10-20%)
  • juvenile chronic polyarthritis (10-20%)
  • ankylosing spondylitis (10-20%)
  • psoriatic arthritis (10-20%)

Compartment

• perinuclear

Pathology

• autoantibody directed against myeloperoxidase or against leukocyte elastase (proteinase-3), lactoferrin

More general terms

• anti-neutrophil cytoplasmic antibody (ANCA)

More specific terms

• lactoferrin antibody in serum

Additional terms

• elastase-2; neutrophil elastase; leukocyte elastase; medullasin; bone marrow serine protease ( ELA2, ELANE)
• lactotransferrin; lactoferrin; talalactoferrin; contains: kaliocin-1; lactoferroxin-A; lactoferroxin-B; lactoferroxin-C (LTF, LF)
• myeloperoxidase (MPO)
• myeloperoxidase antibody in body fluid
• neutrophil or polymorphonuclear leukocyte (PMN, poly)
• pANCA in serum; anti-myeloperoxidase in serum; anti-leukocyte elastase in serum